JP2016502997A - 免疫無防備状態の集団において使用するためのワクチン組成物 - Google Patents

免疫無防備状態の集団において使用するためのワクチン組成物 Download PDF

Info

Publication number
JP2016502997A
JP2016502997A JP2015547078A JP2015547078A JP2016502997A JP 2016502997 A JP2016502997 A JP 2016502997A JP 2015547078 A JP2015547078 A JP 2015547078A JP 2015547078 A JP2015547078 A JP 2015547078A JP 2016502997 A JP2016502997 A JP 2016502997A
Authority
JP
Japan
Prior art keywords
acid
composition
vaccine
group
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502997A5 (https=
Inventor
ハンス アルヴィドソン
ハンス アルヴィドソン
アンナ−カリン マルタイス
アンナ−カリン マルタイス
Original Assignee
ユーロシネ ヴァクシンズ アクチエボラーグ
ユーロシネ ヴァクシンズ アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーロシネ ヴァクシンズ アクチエボラーグ, ユーロシネ ヴァクシンズ アクチエボラーグ filed Critical ユーロシネ ヴァクシンズ アクチエボラーグ
Publication of JP2016502997A publication Critical patent/JP2016502997A/ja
Publication of JP2016502997A5 publication Critical patent/JP2016502997A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
JP2015547078A 2012-12-17 2013-12-17 免疫無防備状態の集団において使用するためのワクチン組成物 Pending JP2016502997A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
EP12197522.1 2012-12-17
PCT/EP2013/077007 WO2014095944A1 (en) 2012-12-17 2013-12-17 Vaccine composition for use in immuno-compromised populations

Publications (2)

Publication Number Publication Date
JP2016502997A true JP2016502997A (ja) 2016-02-01
JP2016502997A5 JP2016502997A5 (https=) 2016-12-01

Family

ID=47358019

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015547078A Pending JP2016502997A (ja) 2012-12-17 2013-12-17 免疫無防備状態の集団において使用するためのワクチン組成物
JP2015547077A Pending JP2016502996A (ja) 2012-12-17 2013-12-17 ナイーブな対象のためのワクチン組成物
JP2019049330A Pending JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015547077A Pending JP2016502996A (ja) 2012-12-17 2013-12-17 ナイーブな対象のためのワクチン組成物
JP2019049330A Pending JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Country Status (12)

Country Link
US (2) US11065325B2 (https=)
EP (4) EP2742952A1 (https=)
JP (3) JP2016502997A (https=)
KR (3) KR20150132092A (https=)
CN (3) CN104884085A (https=)
AU (2) AU2013360890B2 (https=)
BR (2) BR112015014243A8 (https=)
CA (2) CA2895023A1 (https=)
HK (2) HK1212611A1 (https=)
MX (2) MX2015007688A (https=)
RU (2) RU2661408C2 (https=)
WO (2) WO2014095943A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101857839B1 (ko) * 2010-09-30 2018-05-14 유로씨네 백신즈 에이비 개선된 백신 조성물들
KR20230154072A (ko) 2014-09-26 2023-11-07 세퀴러스 유케이 리미티드 면역손상된 대상체의 백신 접종
EP3197487B1 (en) 2014-09-26 2022-08-03 Seqirus UK Limited Vaccination of immunocompromised subjects
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135520B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
HUE069425T2 (hu) * 2020-04-16 2025-03-28 Bayer Ag Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
HUE069397T2 (hu) * 2020-04-16 2025-03-28 Bayer Ag Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A2 (en) * 2022-01-10 2024-11-20 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
ES2352671T3 (es) 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BARAS B, ET AL.: "Longevity of the protective immune response induced after vaccination with one or two doses of AS03A", VACCINE, vol. 29, no. 11, JPN6018013960, 13 January 2011 (2011-01-13), pages 2092 - 2099, ISSN: 0003921325 *
BARAS B, ET AL.: "Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets", VACCINE, vol. 29, no. 11, JPN6018013963, 14 January 2011 (2011-01-14), pages 2120 - 2126, ISSN: 0003921326 *
LAMBKIN R, ET AL.: "Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-", VACCINE, vol. Vol.22, No.31-32, JPN6018013958, 2004, pages 4390 - 4396, ISSN: 0003921324 *
PETERSSON P, ET AL.: "The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after i", VACCINE, vol. 28, no. 39, JPN6017028498, 2010, pages 6491 - 6497, ISSN: 0003921320 *
出口 安裕: "インフルエンザワクチン 高齢者・ハイリスク者・医療介護従事者への接種", 臨牀と研究, vol. 第８１巻，１２号, JPN6017022992, December 2004 (2004-12-01), pages 1938 - 1942, ISSN: 0003921322 *
大藤 さとこ ほか: "インフルエンザワクチンの接種対象", 日本公衆衛生雑誌, vol. 第５４巻，第６号, JPN6017022995, 15 June 2007 (2007-06-15), pages 361 - 367, ISSN: 0003921321 *
相内 章 ほか: "経鼻投与型インフルエンザワクチンの実用化に向けて", インフルエンザ, vol. 第１３巻，第３号, JPN6017028500, October 2012 (2012-10-01), pages 199 - 204, ISSN: 0003780579 *
菅谷 憲夫: "インフルエンザワクチン", 小児科診療, vol. 第６７巻，第１１号, JPN6017022998, 2004, pages 1913 - 1918, ISSN: 0003921323 *
長谷川 秀樹: "経鼻粘膜投与型インフルエンザワクチンの開発", THE LUNG-PERSPECTIVES, vol. 第２０巻，第４号, JPN6017028503, November 2012 (2012-11-01), pages 418 - 422, ISSN: 0003780580 *

Also Published As

Publication number Publication date
BR112015014174A2 (pt) 2017-07-11
AU2013360889C1 (en) 2017-06-08
EP3431101A1 (en) 2019-01-23
AU2013360890A1 (en) 2015-07-02
US20150306204A1 (en) 2015-10-29
MX2015007753A (es) 2016-01-08
EP2931308B1 (en) 2018-10-10
US20150306205A1 (en) 2015-10-29
AU2013360889B2 (en) 2016-12-01
RU2661407C2 (ru) 2018-07-16
RU2015129028A (ru) 2017-01-23
JP2016502996A (ja) 2016-02-01
EP2742952A1 (en) 2014-06-18
US11065325B2 (en) 2021-07-20
BR112015014243A8 (pt) 2019-10-08
RU2015129077A (ru) 2017-01-23
CN112826929A (zh) 2021-05-25
BR112015014243A2 (pt) 2017-07-11
CA2895028A1 (en) 2014-06-26
WO2014095944A1 (en) 2014-06-26
HK1213492A1 (zh) 2016-07-08
JP2019112448A (ja) 2019-07-11
KR20150132093A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
EP2931307A1 (en) 2015-10-21
HK1212611A1 (zh) 2016-06-17
EP2931308A1 (en) 2015-10-21
AU2013360890B2 (en) 2017-04-13
MX2015007688A (es) 2015-09-07
KR20150132092A (ko) 2015-11-25
WO2014095943A1 (en) 2014-06-26
CN104884085A (zh) 2015-09-02
CN104870010A (zh) 2015-08-26
AU2013360889A1 (en) 2015-07-02
RU2661408C2 (ru) 2018-07-16
CA2895023A1 (en) 2014-06-26
KR20210007042A (ko) 2021-01-19

Similar Documents

Publication Publication Date Title
AU2013360890B2 (en) Vaccine composition for use in immuno-compromised populations
Tomar et al. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge
US20160144021A1 (en) Vaccine Composition And Method Of Use
JP6564367B2 (ja) 併用免疫原性組成物
CN102648001A (zh) 含佐剂疫苗制剂
JP2009209086A (ja) 粘膜投与型ワクチン
US8535683B2 (en) Intranasal or inhalational administration of virosomes
AU2007228736B2 (en) Intranasal influenza vaccine based on virosomes
Adam et al. VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine
CN101405027B (zh) 基于病毒颗粒的鼻内流感疫苗
Willis The Effect of Maternal Antibodies on Anti-viral Immunity in Infant Mice
Sanchez Sanchez et al. Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
US20080038294A1 (en) Intranasal or inhalational administration of virosomes
Yoshita Bhide et al. pter 2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181119